Apatinib and gamabufotalin co-loaded lipid/Prussian blue nanoparticles for synergistic therapy to gastric cancer with metastasis
10.1016/j.jpha.2023.11.011
- Author:
Chen BINLONG
1
,
2
;
Zhao YANZHONG
;
Lin ZICHANG
;
Liang JIAHAO
;
Fan JIALONG
;
Huang YANYAN
;
He LEYE
;
Liu BIN
Author Information
1. Health Management Center,The Third Xiangya Hospital,Central South University,Changsha,410013,China
2. Department of Urology,The Third Xiangya Hospital,Central South University,Changsha,410013,China
- Keywords:
Apatinib;
Gamabufotalin;
Lipid/Prussian blue nanoparticles;
Gastric cancer
- From:
Journal of Pharmaceutical Analysis
2024;14(5):707-721
- CountryChina
- Language:Chinese
-
Abstract:
Due to the non-targeted release and low solubility of anti-gastric cancer agent,apatinib(Apa),a first-line drug with long-term usage in a high dosage often induces multi-drug resistance and causes serious side effects.In order to avoid these drawbacks,lipid-film-coated Prussian blue nanoparticles(PB NPs)with hyaluronan(HA)modification was used for Apa loading to improve its solubility and targeting ability.Furthermore,anti-tumor compound of gamabufotalin(CS-6)was selected as a partner of Apa with reducing dosage for combinational gastric therapy.Thus,HA-Apa-Lip@PB-CS-6 NPs were constructed to synchro-nously transport the two drugs into tumor tissue.In vitro assay indicated that HA-Apa-Lip@PB-CS-6 NPs can synergistically inhibit proliferation and invasion/metastasis of BGC-823 cells via downregulating vascular endothelial growth factor receptor(VEGFR)and matrix metalloproteinase-9(MMP-9).In vivo assay demonstrated strongest anti-tumor growth and liver metastasis of HA-Apa-Lip@PB-CS-6 NPs adminis-tration in BGC-823 cells-bearing mice compared with other groups due to the excellent penetration in tumor tissues and outstanding synergistic effects.In summary,we have successfully developed a new nanocomplexes for synchronous Apa/CS-6 delivery and synergistic gastric cancer(GC)therapy.
